Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Pathol Res Pract ; 220: 153379, 2021 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-33721619

RESUMO

Colorectal cancer (CRC) is a heterogeneous disease with different genetic and molecular backgrounds, leading to a diverse patient prognosis and treatment response. Four consensus molecular subtypes (CMS 1-4) have recently been proposed based on transcriptome profiling. A clinically practical immunohistochemistry (IHC) based CMS classifier consisting of the four markers FRMD6, ZEB1, HTR2B, and CDX2 was then demonstrated. However, the IHC-CMS classifier did not distinguish between CMS2 and CMS3 tumours. In this study, we have applied the proposed transcriptome based and IHC-based CMS classifiers in a CRC cohort of 65 patients and found a concordance of 77.5 %. Further, we modified the IHC-CMS classifier by analysing the differentially expressed genes between CMS2 and CMS3 tumours using RNA-sequencing data from the TCGA dataset. The result showed that WNT signalling was among the most upregulated pathways in CMS2 tumours, and the expression level of CTNNB1 (encoding ß-catenin), a WNT pathway hallmark, was significantly upregulated (P = 1.15 × 10-6). We therefore introduced nuclear ß-catenin staining to the IHC-CMS classifier. Using the modified classifier in our cohort, we found a 71.4 % concordance between the IHC and RNA-sequencing based CMS classifiers. Moreover, ß-catenin staining could classify 16 out of the 19 CMS2/3 tumours into CMS2 or CMS3, thereby showing an 84.2 % concordance with the RNA-sequencing-based classifier. In conclusion, we evaluated CMS classifiers based on transcriptome and IHC analysis. We present a modified IHC panel that categorizes CRC tumours into the four CMS groups. To our knowledge, this is the first study using IHC to identify all four CMS groups.


Assuntos
Biomarcadores Tumorais/análise , Neoplasias Colorretais/química , Imuno-Histoquímica , Idoso , Idoso de 80 Anos ou mais , Biomarcadores Tumorais/genética , Fator de Transcrição CDX2/análise , Neoplasias Colorretais/classificação , Neoplasias Colorretais/genética , Neoplasias Colorretais/patologia , Proteínas do Citoesqueleto/análise , Feminino , Perfilação da Expressão Gênica , Humanos , Masculino , Proteínas de Membrana/análise , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Receptor 5-HT2B de Serotonina/análise , Reprodutibilidade dos Testes , Análise de Sequência de RNA , Transcriptoma , Via de Sinalização Wnt , Homeobox 1 de Ligação a E-box em Dedo de Zinco/análise , beta Catenina/análise
2.
Methods Mol Biol ; 1765: 179-191, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29589308

RESUMO

Colorectal cancer (CRC) is a heterogeneous disease, which can be categorized into distinct consensus molecular subtypes (CMSs). These subtypes differ in both clinical as well as biological properties. The gold-standard classification strategy relies on genome-wide expression data, which hampers widespread implementation. Here we describe an immunohistochemical (IHC) Mini Classifier, a practical tool that, in combination with microsatellite instability testing, delivers objective and accurate scoring to classify CRC patients into the main molecular disease subtypes. It is a robust immunohistochemical-based assay containing four specific stainings (FRMD6, ZEB1, HTR2B, and CDX2) in combination with cytokeratin. We also describe an online tool for classification of individual samples based on scoring parameters of these stainings.


Assuntos
Biomarcadores Tumorais/análise , Neoplasias Colorretais/patologia , Processamento de Imagem Assistida por Computador/métodos , Imuno-Histoquímica/métodos , Instabilidade de Microssatélites , Fator de Transcrição CDX2/análise , Neoplasias Colorretais/genética , Proteínas do Citoesqueleto/análise , Humanos , Imuno-Histoquímica/instrumentação , Internet , Proteínas de Membrana/análise , Microscopia/instrumentação , Microscopia/métodos , Receptor 5-HT2B de Serotonina/análise , Homeobox 1 de Ligação a E-box em Dedo de Zinco/análise
3.
Exp Toxicol Pathol ; 58(2-3): 89-99, 2006 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-16996724

RESUMO

Spontaneous valvulopathy has been described as nodular or segmental thickenings composed of fibromyxoid tissue in the subendocardium of various valve-leaflets in aging rats, but its pathogenesis and significance are incompletely understood. In this study, we examined the 5-hydroxytryptamine 2B receptor (5HT2BR) expression and characterization of extracellular matrix (ECM) components, and related these to the presence of valvulopathy in the mitral valve-leaflet (spontaneous mitral valvulopathy, SMV) of Sprague-Dawley (SD) rats. We also examined hearts from Fischer 344 (F344) rats treated with dl-amphetamine sulfate for 103 weeks to further explore the potential for drug-induced exacerbation of SMV. In SD rats, valve-leaflets with SMV exhibited a greater valve thickness, a higher amount of glycosaminoglycans, a lower amount of collagen and increased number of 5HT2BR-positive cells. Our data on morphology and ECM changes showed a striking similarity between SMV in SD rats and anorexigen-associated valvulopathy in humans, and increased 5HT2BR-positive cells in SMV implies that 5HT2BR may play a role in pathogenesis. Further, increased incidence and severity of SMV in F344 rats by treatment with dl-amphetamine suggest that a drug-induced exacerbation of SMV may exist in rats. However, additional research is needed to confirm a role for 5HT2BR in the pathogenesis of SMV in SD rats, and to further characterize the relationship between dl-amphetamine treatment and exacerbation of SMV in F344 rats.


Assuntos
Envelhecimento/patologia , Anfetamina/toxicidade , Glicosaminoglicanos/análise , Valva Mitral/patologia , Receptor 5-HT2B de Serotonina/análise , Animais , Feminino , Masculino , Valva Mitral/química , Valva Mitral/efeitos dos fármacos , Ratos , Ratos Endogâmicos F344 , Ratos Sprague-Dawley
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA